Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy

• DOI: 10.2147/ijn.s174909
• Publication Date: 2018-10-29T20:52:58Z
• Authors: Yu Xia; Yi Chen; Liang Hua; Mingqi Zhao; Tiantian Xu; Changbing Wang; Yinghua Li; Bing Zhu
• Keywords: Cancer Therapy

Selenium nanoparticles (SeNPs) loaded with chemotherapeutic drugs provided a novel perspective for cancer therapy.Here, SeNPs were modified cyclic peptide (Arg-Gly-Asp-d-Phe-Cys [RGDfC]) to fabricate tumor-targeting delivery carrier RGDfC-SeNPs and, then, doxorubicin (DOX) was the surface of improving antitumor efficacy DOX in non-small-cell lung carcinoma therapy.The chemical structure characterization RGDfC-Se@DOX showed that successfully prepare functionalized drug system RGDfC-Se@DOX. exhibited effective cellular uptake A549 cells and entered mainly by clathrin-mediated endocytosis pathway. Compared free or Se@DOX at equivalent dose DOX, greater activity inhibit cells' proliferation migration/invasion induce apoptosis. More importantly, compared passive targeting Se@DOX, active more significant vivo.Taken together, may be promising candidate therapy.